Roth/MKM Launches Buy Coverage on Insmed with $212 Price Objective
Roth/MKM has initiated a Buy rating on Insmed (NASDAQ:INSM), setting a $212 price target that indicates significant potential appreciation from present levels. The firm's analysis points to the strong future prospects of Insmed's Brinsupri and Arikayce therapies, underpinned by favorable trial expectations and market adoption. Despite recent revenu…